Max Schmauß

4.1k total citations · 1 hit paper
101 papers, 2.3k citations indexed

About

Max Schmauß is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Max Schmauß has authored 101 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Psychiatry and Mental health, 28 papers in Pharmacology and 24 papers in Clinical Psychology. Recurrent topics in Max Schmauß's work include Schizophrenia research and treatment (36 papers), Treatment of Major Depression (28 papers) and Bipolar Disorder and Treatment (19 papers). Max Schmauß is often cited by papers focused on Schizophrenia research and treatment (36 papers), Treatment of Major Depression (28 papers) and Bipolar Disorder and Treatment (19 papers). Max Schmauß collaborates with scholars based in Germany, United States and Belgium. Max Schmauß's co-authors include G. Laakmann, Hanns Hippius, W.E. Bunney, Andreas Erfurth, Thomas Messer, Dieter Naber, Markus Jäger, Michael Riedel, Gerd Laux and Isabella Heuser and has published in prestigious journals such as PLoS ONE, The British Journal of Psychiatry and Psychopharmacology.

In The Last Decade

Max Schmauß

93 papers receiving 2.2k citations

Hit Papers

Neuropsychopharmacology 1990 2026 2002 2014 1990 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neuropsychopharmacology
    1990 1.2k citations Max Schmauß et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Schmauß Germany 21 836 659 423 355 350 101 2.3k
Kunitoshi Kamijima Japan 30 775 0.9× 540 0.8× 542 1.3× 525 1.5× 342 1.0× 108 3.0k
David B Menkes New Zealand 29 695 0.8× 839 1.3× 577 1.4× 513 1.4× 487 1.4× 121 3.0k
Maria A. Oquendo United States 21 755 0.9× 599 0.9× 523 1.2× 206 0.6× 520 1.5× 31 2.4k
Koichi Otani Japan 31 1.4k 1.6× 688 1.0× 570 1.3× 507 1.4× 695 2.0× 204 3.5k
Raben Rosenberg Denmark 31 974 1.2× 627 1.0× 407 1.0× 341 1.0× 846 2.4× 83 3.1k
A.J.M. Loonen Netherlands 26 916 1.1× 581 0.9× 235 0.6× 369 1.0× 251 0.7× 161 2.4k
Y.D. Lapierre Canada 27 1.1k 1.4× 741 1.1× 521 1.2× 347 1.0× 560 1.6× 139 2.6k
Andreas Erfurth Germany 27 1.3k 1.5× 556 0.8× 488 1.2× 313 0.9× 444 1.3× 139 2.6k
Akihito Suzuki Japan 25 900 1.1× 379 0.6× 382 0.9× 257 0.7× 313 0.9× 156 2.2k
Christopher Reist United States 31 954 1.1× 362 0.5× 833 2.0× 228 0.6× 341 1.0× 77 2.7k

Countries citing papers authored by Max Schmauß

Since Specialization
Citations

This map shows the geographic impact of Max Schmauß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Schmauß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Schmauß more than expected).

Fields of papers citing papers by Max Schmauß

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Schmauß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Schmauß. The network helps show where Max Schmauß may publish in the future.

Co-authorship network of co-authors of Max Schmauß

This figure shows the co-authorship network connecting the top 25 collaborators of Max Schmauß. A scholar is included among the top collaborators of Max Schmauß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Schmauß. Max Schmauß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meisinger, Christa, et al.. (2023). Are cytokine profiles associated with the cognitive performance of adults with severe major depression?. Journal of Psychiatric Research. 166. 32–39.
2.
Heinze, Martin, et al.. (2023). Unterstützung für Familien mit einem psychisch erkrankten Elternteil. Der Nervenarzt. 95(1). 18–27.
3.
Hamann, Johannes, et al.. (2020). Implementing shared decision-making on acute psychiatric wards: a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS). Epidemiology and Psychiatric Sciences. 29. e137–e137. 36 indexed citations
4.
Kilian, Reinhold, Annabel Sandra Mueller‐Stierlin, Petra Beschoner, et al.. (2020). Masculinity norms and occupational role orientations in men treated for depression. PLoS ONE. 15(5). e0233764–e0233764. 9 indexed citations
5.
Kösters, Markus, et al.. (2016). Qualitätsindikatoren für die Behandlung von Menschen mit Schizophrenie – Ergebnisse einer Anwendungsstudie. Psychiatrische Praxis. 44(3). 163–171. 6 indexed citations
6.
Schennach, Rebecca, Michael Riedel, Michael Obermeier, et al.. (2014). What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?. European Psychiatry. 30(1). 43–50. 19 indexed citations
7.
Schmauß, Max, Vlado Jukić, Alberto Siracusano, et al.. (2012). Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Current Medical Research and Opinion. 28(8). 1395–1404. 13 indexed citations
8.
Schennach, Rebecca, Sebastian Meyer, Florian Seemüller, et al.. (2012). Response trajectories in “real-world” naturalistically treated schizophrenia patients. Schizophrenia Research. 139(1-3). 218–224. 23 indexed citations
9.
Riedel, Michael, Stefan Leucht, Eckart Rüther, Max Schmauß, & Hans‐Jürgen Möller. (2011). Critical trial-related criteria in acute schizophrenia studies. European Archives of Psychiatry and Clinical Neuroscience. 262(2). 151–155. 2 indexed citations
10.
Schennach-Wolff, Rebecca, Sebastian Meyer, Florian Seemüller, et al.. (2011). Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. Journal of Psychiatric Research. 45(12). 1639–1647. 20 indexed citations
11.
Schennach-Wolff, Rebecca, Michael Obermeier, Florian Seemüller, et al.. (2010). Does Clinical Judgment of Baseline Severity and Changes in Psychopathology Depend on the Patient Population?. Journal of Clinical Psychopharmacology. 30(6). 726–731. 26 indexed citations
12.
Schennach-Wolff, Rebecca, Markus Jäger, Florian Seemüller, et al.. (2009). Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Acta Psychiatrica Scandinavica. 121(5). 359–370. 20 indexed citations
13.
Schmauß, Max & Thomas Messer. (2009). Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen?. Fortschritte der Neurologie · Psychiatrie. 77(6). 316–325. 4 indexed citations
14.
Schmauß, Max, et al.. (2007). Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International Clinical Psychopharmacology. 22(2). 85–92. 27 indexed citations
15.
Normann, Claus, et al.. (2006). Initial Treatment of Severe Acute Psychosis with Fast Orally Disintegrating Risperidone Tablets. Pharmacopsychiatry. 39(6). 209–212. 18 indexed citations
16.
17.
Schmauß, Max, et al.. (2004). Prävalenz psychischer Erkrankungen in der Umweltmedizinischen Ambulanz einer Klinik der Maximalversorgung. PubMed. 31. 24–25. 2 indexed citations
18.
Schmauß, Max, et al.. (2004). Rehospitalisierungsrate ersterkrankter schizophrener Patienten unter atypischer neuroleptischer Medikation. PubMed. 31. 38–40. 6 indexed citations
19.
Fritze, J., et al.. (2001). Vergütung psychiatrischer Leistungen im neuen Krankenhaus-Entgeltsystem (DRG-System). Der Nervenarzt. 72(11). 894–896. 5 indexed citations
20.
Rottach, Klaus G., et al.. (2000). Valproinsäure als Phasenprophylaktikum. Der Nervenarzt. 71(5). 401–403. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kunitoshi Kamijima Breakdown of academic impact, for papers by David B Menkes Breakdown of academic impact, for papers by Maria A. Oquendo Breakdown of academic impact, for papers by Koichi Otani Breakdown of academic impact, for papers by Raben Rosenberg Breakdown of academic impact, for papers by A.J.M. Loonen Breakdown of academic impact, for papers by Y.D. Lapierre Breakdown of academic impact, for papers by Andreas Erfurth Breakdown of academic impact, for papers by Akihito Suzuki Breakdown of academic impact, for papers by Christopher Reist
Rankless by CCL
2026